#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12354	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2224	550.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1465	1465	C	716	C	656	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22574	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3513	640.5	0	.	n	.	0	T695C	SNP	695	695	T	990	990	C	647	C	607	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22574	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3513	640.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2266	2266	C	705	C,T,G	641,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22574	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3513	640.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2892	2892	T	689	T,C,G	500,140,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22574	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3513	640.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2340	2340	A	745	A	687	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1798	folP	852	852	100.0	folP.l15.c4.ctg.1	1642	109.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1050	1052	AGC	188;189;187	A;G;C	179;180;178	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3237	150.7	1	SNP	p	S91F	0	.	.	271	273	TCC	514	516	TCC	160;159;160	T;C;C	150;148;148	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3237	150.7	1	SNP	p	D95G	0	.	.	283	285	GAC	526	528	GAC	157;160;161	G;A;C	147;148;146	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3237	150.7	1	SNP	p	D95N	0	.	.	283	285	GAC	526	528	GAC	157;160;161	G;A;C	147;148;146	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1416	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1245	112.6	1	SNP	p	G45D	1	.	.	133	135	GAC	515	517	GAC	146;146;146	G;A;C	140;141;140	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	736	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	952	76.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2916	157.9	1	SNP	p	D86N	0	.	.	256	258	GAC	533	535	GAC	187;187;188	G;A;C	169;167;172	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2916	157.9	1	SNP	p	S87I	0	.	.	259	261	AGT	536	538	AGT	187;187;188	A;G;T	171;170;168	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2916	157.9	1	SNP	p	S87W	0	.	.	259	261	AGT	536	538	AGT	187;187;188	A;G;T	171;170;168	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2916	157.9	1	SNP	p	S87R	0	.	.	259	261	AGT	536	538	AGT	187;187;188	A;G;T	171;170;168	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4624	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2916	157.9	1	SNP	p	S88P	0	.	.	262	264	TCC	539	541	TCC	190;193;195	T;C;C	173;177;179	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3732	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2754	135.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1554	1556	GGC	193;193;194	G;G;C	180;179;177	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1281	1283	GCA	165;161;163	G;C;A	155;150;154	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1284	1286	ATC	164;166;165	A;T;C	153;156;155	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1296	1298	GTG	169;168;164	G;T;G	156;158;152	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1296	1298	GTG	169;168;164	G;T;G	156;158;152	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1800	1802	ACC	172;174;177	A;C;C	147;150;154	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1854	1856	GCG	165;164;165	G;C;G	146;136;145	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1854	1856	GCG	165;164;165	G;C;G	146;136;145	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1977	1979	GGC	153;150;149	G;G;C,T	145;141;142,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1986	1988	GGC	148;149;149	G;G;C	139;139;139	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3384	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2453	137.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2004	2006	CCG	145;146;144	C,G;C;G	110,3;113;110	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4716	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3189	147.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2208	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1684	130.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	549	549	C	164	C	144	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	I45V	NONSYN	133	135	ATT	446	448	GTT	178;179;180	G;T;T	162;160;162	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	N121S	NONSYN	361	363	AAC	674	676	AGC	161;160;159	A;G;C	148;148;150	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	677	679	AAA	159;160;159	A;A;A	151;152;152	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	Q143E	NONSYN	427	429	CAA	740	742	GAA	142;140;140	G;A,G;A	136;135,1;137	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	764	766	GCA	161;160;160	G;C;A	148;146;146	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	K207_M208insK	INS	619	619	A	932	932	A	185	A	172	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	A212S	NONSYN	634	636	GCA	950	952	TCA	184;183;181	T;C;A	175;175;173	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2160	porB1b	1038	1038	97.23	porB1b.l15.c17.ctg.1	1502	143.2	0	.	p	.	0	Y251fs	FSHIFT	751	751	T	1067	1067	T	172	T	166	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8276	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4868	169.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1976	1978	AAT	204;203;203	A;A;T	190;189;188	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	866	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1041	82.7	1	SNP	p	V57M	1	.	.	169	171	ATG	538	540	ATG	187;187;187	A;T;G	173;173;172	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
